Diabetes in the Elderly

Medical Clinics of North America

Volumn 90, Issue 5, 2006, Pages 909-923

  Meneilly, Graydon S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; FLUOXETINE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

AGED; CLINICAL FEATURE; COGNITION; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; UNITED STATES;

EID: 33748512579     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2006.05.011     Document Type: Review

References (77)

1. Harris M.I., Flegal K.M., Cowie C.C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Diabetes Care 21 (1998) 518-524
2. Kahn C.R. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43 (1994) 1066-1984
3. Vaag A., Henriksen J.E., Madsbad S., et al. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest 95 (1995) 690-698
4. Skarfors E.T., Selinus K.I., and Lithell H.O. Risk factors for developing non-insulin-dependent diabetes. A 10-year follow-up of men in Uppsala. BMJ 303 (1991) 755-760
5. Meneilly G.S., and Tessier D. Diabetes in elderly adults. J Gerontol 56A (2001) M5-M13
6. Jackson R.A. Mechanisms of age-related glucose intolerance. Diabetes Care 13 Suppl 2 (1990) 9-19
7. Barzilay J.I., Abraham L., Heckbert S., et al. The relation of markers of inflammation to the development of glucose disorders in the elderly. Diabetes 50 (2001) 2384-2389
8. Kanaya A.M., Harris T., Goodpaster B.H., et al. Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care 27 (2004) 1375-1380
9. Lechleitner M., Herold M., Dzien-Bischinger C., et al. Tumour necrosis factor-alpha plasma levels in elderly patients with type 2 diabetes mellitus-observations over 2 years. Diabet Med 19 (2002) 949-953
10. Oh J.-Y., Barrett-Connor E., Wedick N.M., et al. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care 25 (2002) 55-60
11. Pandit M.K., Burke J., Gustafson A.B., et al. Drug induced disorders of glucose intolerance. Ann Intern Med 118 (1993) 529-539
12. DeFronzo R.A. Lilly Lecture 1987. The triumvirate: b-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37 (1988) 667-687
13. Meneilly G.S., Hards L., Tessier D., et al. NIDDM in the elderly. Diabetes Care 19 (1996) 1320-1325
14. Meneilly G.S., and Elliott T. Metabolic alterations in middle-aged and elderly obese patients with type 2 diabetes. Diabetes Care 22 (1999) 112-118
15. Meneilly G.S., and Elahi D. Metabolic alterations in middle-aged and elderly lean patients with type 2 diabetes. Diabetes Care 28 (2005) 1498-1499
16. Arner P., Pollare T., and Lithell H. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 4 (1991) 483-487
17. Paolisso G., Gambardella A., Verza M., et al. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 6 (1992) 175-179
18. Best J.D., Kahn S.E., Ader M., et al. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care 19 (1996) 1018-1030
19. Forbes A., Elliot T., Tildesley H., et al. Alterations in non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes 47 (1998) 1915-1919
20. McCarthy M.I., Hitman G.A., Hitchins M., et al. Glucokinase gene polymorphisms: a genetic marker for glucose intolerance in cohort of elderly Finnish men. Diabet Med 10 (1993) 198-204
21. Laakso M., Malkki M., Kekalainen P., et al. Glucokinase gene variants in subjects with late-onset NIDDM and impaired glucose tolerance. Diabetes Care 18 (1995) 398-400
22. Obermaier-Kusser B., White M.F., Pongratz D.E., et al. A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin receptor from patients with non-insulin-dependent diabetes mellitus. J Biol Chem 264 (1989) 9497-9504
23. Gambert S.R. Atypical presentation of diabetes in the elderly. Clin Geriatr Med 6 (1990) 721-729
24. Morley J.E., and Kaiser F.E. Unique aspects of diabetes mellitus in the elderly. Clin Geriatr Med 6 (1990) 693-702
25. Sinclair A.J., Robert I.M., and Croxson S.C.M. Mortality in older people with diabetes mellitus. Diabet Med 14 (1996) 639-647
26. Spiers N.A., Matthews R.J., Jagger C., et al. Diseases and impairments as risk factors for onset of disability in the older population in England and Wales: findings from the Medical Research Council Cognitive Function and Ageing Study. J Gerontol 60A (2005) 248-254
27. Seeman T., and Chen X. Risk and protective factors for physical functioning in older adults with and without chronic conditions: MacArthur studies of successful aging. J Gerontol B Psychol Sci Soc Sci 57B (2002) S135-S144
28. Wray L.A., Ofstedal M.B., Langa K.M., et al. The effect of diabetes on disability in middle-aged and older adults. J Gerontol 60A (2005) 1206-1211
29. Al Snih S., Fisher M.N., Raji M.A., et al. Diabetes mellitus and incidence of lower body disability among older Mexican Americans. J Gerontol A Biol Sci Med Sci 60 (2005) 1152-1156
30. Maggi S., Noale M., Gallina P., et al., for the ILS Group. Physical disability among older Italians with diabetes. The ILSA Study. Diabetologia 47 (2004) 1957-1962
31. Maciejewski M.L., and Maynard C. Diabetes-related utilization and costs for inpatient and outpatient services in the Veterans Administration. Diabetes Care 27 (2004) B69-B73
32. Bertoni A.G., Hundley W.G., Massing M.W., et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27 (2004) 699-703
33. Mayfield J.A., Reiber G.E., Maynard C., et al. The epidemiology of lower-extremity disease in veterans with diabetes. Diabetes Care 27 (2004) B39-B44
34. Nichols G.A., Gullion C.M., Koro C.E., et al. The incidence of congestive heart failure in type 2 diabetes. Diabetes Care 27 (2004) 1879-1884
35. Gregg E.W., Sorlie P., Paulose-Ram R., et al. Prevalence of lower-extremity disease in the US adult population over 40 years of age with and without diabetes. Diabetes Care 27 (2004) 1591-1597
36. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314 7093 (1997) 1512-1515
37. Meneilly G.S., Cheung E., and Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 43 (1994) 403-410
38. Thomson F.J., Masson E.A., Leeming J.T., et al. Lack of knowledge of symptoms of hypoglycaemia by elderly diabetic patients. Age Aging 20 (1991) 404-406
39. Meneilly G.S., Cheung E., Tessier D., et al. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48 (1993) M117-M121
40. Gradman T.J., Laws A., Thompson L.W., et al. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 41 (1993) 1305-1312
41. Janson J., Laedtke T., Parisi J.E., et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53 (2004) 474-481
42. Beeri M.S., Silverman J.M., Davis K.L., et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 60 (2005) 471-475
43. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
44. Chiasson J.L., Josse R.G., Gomis R., et al., for The STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. JAMA 290 (2003) 486-494
45. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 28 (2005) S37-S42
46. Hoerger T.J., Harris R., Hicks K.A., et al. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 140 (2004) 689-699
47. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
48. UK Prospective Diabetes Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352 (1998) 837-853
49. European Diabetes Working Party for Older People 2001-2004. Clinical guidelines for type 2 diabetes mellitus. Available at: http://www.euroage-diabetes.com. Accessed November 2003.
50. The DECODE Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2 hour diagnostic criteria. Arch Intern Med 161 (2001) 397-405
51. Braun A., Muller U.A., Muller R., et al. Structured treatment and teaching of patients with type 2 diabetes mellitus and impaired cognitive function-the DICOF trial. Diabet Med 21 (2004) 999-1006
52. Curb J.D., Pressel S.L., Cutler J.A., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276 (1996) 1886-1891
53. Tuomilehto J., Rastenyte D., Birkenhäger W.H., et al., for the Systolic Hypertension in Europe Trial investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340 (1999) 677-684
54. Voyaki S.M., Staessen J.A., Thijs L., et al., for Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J Hypertens 19 (2001) 511-519
55. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 342 (2000) 145-153
56. Julius S., Kjeldsen S.E., Weber M., et al., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlopidine: the VALUE randomized trial. Lancet 363 (2004) 2022-2030
57. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
58. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361 (2003) 2005-2016
59. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30.
60. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 364 (2004) 685-696
61. Dunstan D.W., Daly R.M., Owen N., et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care 25 (2002) 1729-1736
62. Ibañez J., Izquierdo M., Argüelles I., et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care 28 (2005) 662-667
63. Johnston P.S., Lebovitz H.E., Coniff R.F., et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 83 (1998) 1515-1522
64. Chiasson J.L., Josse R.G., Gomis R., et al., for The STOP-NIDDM Trial Research Group. Acarbose prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359 (2002) 2072-2077
65. Rajagopalan R., Perez A., Ye Z., et al. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drugs Aging 21 (2004) 259-271
66. Rosenstock J., Corrao P.J., Goldberg R.B., et al. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. Clin Ther 15 (1993) 1031-1040
67. Brodows R.G. Benefits and risks with glyburide and glipazide in elderly NIDDM patients. Diabetes Care 15 (1992) 75-80
68. Tessier D., Dawson K., Tetrault J.P., et al. Glibenclamide vs glicazide in type 2 diabetes of the elderly. Diabet Med 11 (1994) 974-980
69. Drouin P., Standl E., and for the Diamicron MR Study Group. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab 6 (2004) 414-421
70. Holstein A., Plaschke A., and Eick-Hartwig E. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17 (2001) 467-473
71. Del Prato S., Heine R.J., Keilson L., et al. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care 26 (2003) 2075-2080
72. Hendra T.J., and Taylor C.D. A randomized trial of insulin on well-being and carer strain in elderly type 2 diabetic subjects. J Diabetes Complications 18 (2004) 148-154
73. Connolly V.M., Gallagher A., and Kesson C.M. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med 12 (1994) 416-418
74. Meneilly G.S., Greig N., Tildesley H., et al. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 26 (2003) 2835-2841
75. Wagner G., Montorsi F., Auerbach S., et al. Sildenafil citrate (Viagra) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol 56A (2001) M113-M119
76. Carson C.C., Rajfer J., Eardley I., et al. The efficacy and safety of tadalafil: an update. BJU Int 93 (2004) 1276-1281
77. Tsujimura A., Yamanaka M., Takahashi T., et al. The clinical studies of sildenafil for the ageing male. Int J Androl 25 (2002) 28-33